BioMimetic Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of products for the healing of musculoskeletal injuries and diseases. It offers therapies for orthopedic, sports medicine, and spine applications. The company’s Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB, which is a wound healing and tissue repair stimulator in the body. Its products and product candidates consist of Augment, Augment Injectable, and Augment Rotator Cuff for use in various orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries due to tendon overuse. The company also markets a bone graft substitute line of products for orthopedic indications under the Augmatrix Biocomposite Bone Graft name. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee. As of March 1, 2013, BioMimetic Therapeutics Inc. operates as a subsidiary of Wright Medical Group Inc.